The abstract is read at the publisher; the summary is JClub's.
Once-daily oral alixorexton in adults with narcolepsy type 1 increased Maintenance of Wakefulness Test mean sleep latency at week 6, reaching 28·2 min with 8 mg.
- Why it matters: Orexin 2 receptor agonism is linked to improved wakefulness and cataplexy, but new oral OX2R agents need safety, tolerability, and efficacy confirmation in narcolepsy type 1.
- What they did: In a randomized, double-blind, placebo-controlled phase 2 trial across 46 US/Europe/Australia sites, adults received alixorexton 4 mg, 6 mg, or 8 mg or placebo once daily for 6 weeks, with week-6 MWT mean sleep latency as the primary endpoint.
- The result: At week 6, placebo-corrected least-squares changes in MSL were 22·2 min (4 mg), 24·1 min (6 mg), and 26·0 min (8 mg), with adjusted p=0·0099, p<0·0001, and p<0·0001; treatment-emergent adverse events included pollakiuria and insomnia.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.